MYOLYN was built with the dream of making FES cycling therapy accessible to the millions of people who need it, where they need it – from the comfort and convenience of their own homes. This technology is the cornerstone of what is enabling us to make that dream a reality.
GAINESVILLE, Fla. (PRWEB) March 24, 2020
MYOLYN, LLC, a leading manufacturer of rehab devices for people with lower body weakness or paralysis, announced today that the United States Patent and Trademark Office (USPTO) issued a patent on the Company’s novel functional electrical stimulation (FES) cycling technology. The Company uses the technology in its MyoCycle line of therapy devices designed for use in home and clinical environments. FES cycling therapy is commonly used in rehab hospitals and physical therapy clinics for patients with neurological disorders resulting in lower body weakness or paralysis. These disorders include spinal cord injury, stroke, multiple sclerosis, brain injury, and others. The FDA-cleared benefits of FES include:
- Prevention of muscle atrophy
- Increasing range of motion
- Increasing blood flow
- Relaxation of muscle spasms
The newly patented technology is enabling the Company to transition the therapy from one that is almost exclusively administered in the clinical setting, to one that can be performed at home.
“The MyoCycle uses principles from robotics to automate the set up and optimization of the therapy parameters,” says Matthew Bellman, PhD, MYOLYN’s Chief Technology Officer and an inventor of the patented technology. “This makes the MyoCycle extremely easy to use.”
The MyoCycle works by using adhesive electrode pads placed on the skin over target muscle groups. The electrodes apply small electrical impulses to activate the muscles, even if the patient is weak or paralyzed. MYOLYN’s patented technology controls the timing and intensity of the stimulation so it is patterned to generate a smooth pedaling motion. Additionally, the MyoCycle has a built-in motor that adaptively assists or resists the pedaling motion depending on the user’s abilities.
Alan Hamlet, PhD, founder and Chief Executive Officer of MYOLYN, says the Company has been developing FES cycling technology for over 7 years and has ambitions to make home-based FES cycling therapy a standard for patients with neurological disorders.
“MYOLYN was built with the dream of making FES cycling therapy accessible to the millions of people who need it, where they need it – from the comfort and convenience of their own homes. This technology is the cornerstone of what is enabling us to make that dream a reality.”
MYOLYN’s mission is to improve health and human performance by empowering people to move. The Company designs, manufactures, and markets rehabilitation and therapy devices for people with muscle weakness or paralysis. The Company was founded in 2013 by Ph.D engineers Alan Hamlet and Matthew Bellman and is headquartered in Gainesville, FL. For more information visit http://www.MYOLYN.com.